Latest News

Noah G. Banoub discusses a study finding MacTel2 misdiagnosed in 25.5% of cases, common mimics, misleading imaging, and Encelto's approval.

Topical chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO, Harrow) resulted in less pain f following intravitreal injections in patients undergoing same-day bilateral intravitreal injections.

The Aug. 20-23 meeting in Monterey, California, offers CME across subspecialties alongside sessions on mentorship, career longevity, and research.

ZEISS CLINIC 360 is an all-in-one cloud and browser-based software platform designed to consolidate ophthalmic diagnostic and medical record data into a single, unified patient view.

The FDA issued a recall notice for an eye drop designed to relieve ocular redness, itching, burning, and watery eyes. The Class II recall alerts consumers and physicians to possible temporary or reversible health effects, but serious harm is unlikely.

Neel S. Vaidya, MD, MPH, MBA, on why keratoconus can progress aggressively in children and teens—and how early topographic screening and prompt crosslinking protect long-term vision.

Researchers in the UK have developed a new treatment approach for aniridia-related keratopathy (ARK), a rare genetic ocular disease, namely, a collagen scaffold that delivers limbal epithelial stem cells and stromal stem cells to the area affected by ARK. The treatment resulted in improved ocular surface scores and visual acuities.

CMS payment rates for the FSYX Ocular Pressure Adjusting Pump take effect October 1, 2026, clearing a reimbursement path for the noninvasive glaucoma device.

AI accelerates retina trials and imaging insights, boosts screening access, and raises urgent questions on regulation, privacy, and equity.

The Jack McGovern Coats' Disease Foundation has announced the initiation of new research to develop the first validated animal model of Coats' Disease, a rare eye disorder that primarily affects children.

Phase 3 DURAVYU insert misses key vision endpoint in wet AMD but cuts injections; pivotal LUCIA readout may decide its future.

A roundup of Ophthalmology Times' H1 2026 refractive coverage shows the field moving toward individualized care through adjustable lens outcomes, AI-assisted planning, and refined pediatric myopia monitoring.

Byron Lam, MD, and Benjamin Bakall, MD, PhD, discuss what an FDA approval of tinlarebant could mean for the Stargardt disease type 1 standard of care.